Induction of apoptosis in mouse liver adenoma and carcinoma in vivo by transforming growth factor-beta1

Monika Chabicovsky1, Ute Wastl, Henryk Taper

  • 1Institut für Krebsforschung der Universität Wien, Borschkegasse 8a, 1090, Wien, Austria.

Abstract

Insights

Transforming growth factor beta-1 (TGF-beta1) increases apoptosis in liver tumors. This study shows TGF-beta1 can enhance the elimination of cancer cells in chemically induced liver carcinogenesis models.

Area of Science:

  • Hepatology
  • Cancer Biology
  • Molecular Signaling

Background:

  • Transforming growth factor beta-1 (TGF-beta1) is a key regulator of liver cell proliferation and apoptosis.
  • Dysregulation of TGF-beta1 signaling is implicated in liver cancer development.
  • The in vivo effects of exogenous TGF-beta1 on liver tumor apoptosis remain largely uncharacterized.

Purpose of the Study:

  • To investigate the sensitivity of hepatocytes to the pro-apoptotic effects of TGF-beta1 during chemically induced liver carcinogenesis.
  • To evaluate the impact of TGF-beta1 administration on apoptosis rates in normal liver and preneoplastic/neoplastic lesions.

Main Methods:

  • Liver carcinogenesis was induced in B6C3F1 mice using N-nitrosodiethylamine (NDEA) with or without phenobarbital (PB) treatment.
  • Mice received intravenous injections of TGF-beta1 (56 or 200 microg/kg) before tissue collection.
  • Quantitative histological analysis assessed mitosis and apoptosis in normal liver, putative preneoplastic foci, hepatocellular adenoma, and hepatocellular carcinoma.

Main Results:

  • Apoptosis and mitosis rates were low in normal liver but increased in hepatocellular adenoma (HCA) and hepatocellular carcinoma (HCC).
  • A high dose of TGF-beta1 (200 microg/kg) significantly increased apoptosis in normal liver, HCA, and HCC.
  • The pro-apoptotic effect of TGF-beta1 was most pronounced in lesions from mice treated with NDEA and PB.

Conclusions:

  • Basal apoptosis rates are elevated in liver adenoma and carcinoma compared to normal liver during chemically induced carcinogenesis.
  • Exogenous administration of TGF-beta1 can further enhance apoptosis in liver tumors.
  • TGF-beta1 represents a potential therapeutic cytokine for increasing cancer cell death in liver cancer.